BRAF and malignant colon neoplasm: Similarly, there is evidence that relative to its marginal expression in normal human colorectal cancer (CRC) samples, FAT1 is broadly expressed in primary and metastatic CRC cells, mainly accumulating in the plasma membrane, regardless of KRAS and BRAF mutations, and positively correlated with enhanced cell invasiveness, conversely, when targeted by the FAT1-specific monoclonal antibody, mAb198.3, reduction in cancer growth ensues in colon cancer xenograft model, in vivo [31].